173 related articles for article (PubMed ID: 21859559)
21. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Lockhart AC; Cropp GF; Berlin JD; Donnelly E; Schumaker RD; Schaaf LJ; Hande KR; Fleischer AC; Hannah AL; Rothenberg ML
Am J Clin Oncol; 2006 Apr; 29(2):109-15. PubMed ID: 16601426
[TBL] [Abstract][Full Text] [Related]
22. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.
Farrell MP; Kummar S
Clin Colorectal Cancer; 2003 Feb; 2(4):253-6. PubMed ID: 12620148
[No Abstract] [Full Text] [Related]
23. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
[TBL] [Abstract][Full Text] [Related]
24. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
Berlin J; Posey J; Tchekmedyian S; Hu E; Chan D; Malik I; Yang L; Amado RG; Hecht JR
Clin Colorectal Cancer; 2007 Mar; 6(6):427-32. PubMed ID: 17531105
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer.
Kulig J; Popiela T; Richter P; Klek S
Acta Chir Belg; 2007 Jun; 107(3):297-301. PubMed ID: 17685257
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
[TBL] [Abstract][Full Text] [Related]
28. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926
[TBL] [Abstract][Full Text] [Related]
29. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
[TBL] [Abstract][Full Text] [Related]
30. Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment?
Idelevich E; Man S; Lavrenkov K; Gluzman A; Geffen DB; Shani A
J Chemother; 2004 Oct; 16(5):487-90. PubMed ID: 15565917
[TBL] [Abstract][Full Text] [Related]
31. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
32. Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Hartmann JT; Pintoffl JP; Kröning H; Bokemeyer C; Holtmann M; Höhler T
Onkologie; 2008 May; 31(5):237-41. PubMed ID: 18497512
[TBL] [Abstract][Full Text] [Related]
33. Multicenter phase II study of irinotecan plus bolus fluorouracil/l-leucovorin for metastasic colorectal cancer.
Mishima H; Ikenaga M; Ishida H; Iwamoto S; Morimoto T; Narahara H; Kato T; Tsujie M; Kitai T; Fukunaga M; Nakanishi M; Tsujinaka T; Furukawa H; Taguchi T;
Anticancer Res; 2007; 27(2):1003-8. PubMed ID: 17465234
[TBL] [Abstract][Full Text] [Related]
34. A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
Gennatas C; Papaxoinis G; Michalaki V; Mouratidou D; Andreadis C; Tsavaris N; Pafiti A
J Chemother; 2006 Oct; 18(5):538-44. PubMed ID: 17127232
[TBL] [Abstract][Full Text] [Related]
35. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
36. Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics.
Gaudreault J; Shiu V; Bricarello A; Christian BJ; Zuch CL; Mounho B
Int J Toxicol; 2005; 24(5):357-63. PubMed ID: 16257855
[TBL] [Abstract][Full Text] [Related]
37. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
38. Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience.
Gluzman A; Rubinov K; Mermershtain W; Man S; Ariad S; Lavrenkov K
J Chemother; 2007 Dec; 19(6):739-43. PubMed ID: 18230559
[TBL] [Abstract][Full Text] [Related]
39. The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018).
Lam W; Jiang Z; Guan F; Hu R; Liu SH; Chu E; Cheng YC
BMC Complement Altern Med; 2014 Dec; 14():490. PubMed ID: 25510341
[TBL] [Abstract][Full Text] [Related]
40. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
Price T; Hill M
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
